Quantcast

PTC Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating


Shutterstock photo

One important metric to look for in a stock is an 80 or higher Relative Strength Rating . PTC Therapeutics ( PTCT ) cleared that benchmark Tuesday, with a jump from 79 to 89 Tuesday.

[ibd-display-video id=2385970 width=50 float=left autostart=true] This proprietary rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.

History shows that the best-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves.

See How IBD Helps You Make More Money In Stocks

PTC Therapeutics is building a consolidation with a 22.10 buy point . See if the stock can break out in volume at least 40% above average.

While sales growth fell last quarter from 207% to 82%, earnings-per-share grew 20%, up from 0% in the previous report.

The company holds the No. 57 rank among its peers in the Medical-Biomed/Biotech industry group. Corcept Therapeutics ( CORT ), Vertex Pharmaceuticals ( VRTX ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.

RELATED:

Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Improved Price Performance?

Why Should You Use IBD's Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Stocks
Referenced Symbols: PTCT , CORT , VRTX , LGND


More from Investor's Business Daily

Subscribe






Investor's Business Daily
Contributor:

Investor's Business Daily

Investing








Research Brokers before you trade

Want to trade FX?